PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 36,400 shares, a growth of 23.0% from the August 15th total of 29,600 shares. Based on an average trading volume of 190,100 shares, the short-interest ratio is presently 0.2 days.

PURE Bioscience Price Performance

PURE stock remained flat at $0.23 during mid-day trading on Friday. 10,600 shares of the company's stock were exchanged, compared to its average volume of 164,655. The business has a 50 day moving average of $0.21 and a 200 day moving average of $0.20. PURE Bioscience has a twelve month low of $0.15 and a twelve month high of $0.43.

PURE Bioscience (OTCMKTS:PURE – Get Rating) last issued its earnings results on Tuesday, June 14th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.50 million during the quarter. PURE Bioscience had a negative return on equity of 131.39% and a negative net margin of 131.59%.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.

Featured Articles

• Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
• 3 Banks Worth Considering For Q4
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• Is There a Cure for What is Ailing Teladoc Stock?
• No One Told These 3 Stocks It's a Down Week
• MarketBeat: Week in Review 9/12 – 9/16

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.